Developing and commercializing first-in-class, well-characterized drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies.
PALO ALTO, Calif. , Sept. 1, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in four investor conferences in
- 96% of Patients Achieve Primary Endpoint of > 2 Log Decline in HDV RNA - 58% of Patients Below Limit of Quantitation or Undetectable at Week 24 PALO ALTO, Calif. , Aug. 31, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of
PALO ALTO, Calif. , Aug. 6, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for second quarter 2020 and provided a business update.
